


The requirements for election of species are traversed for the following reasons: The present invention is directed generally to the administration of clioquinol, and the administration of clioquinol and vitamin B12, for the therapy of amyloidosis. The invention is also directed to compositions comprising clioquinol and vitamin B12. The methods and compositions encompassed by the present claims are closely related to one another regardless of the manner of administration (orally, intramuscularly, parenterally or intradermally), or the administration regimen used (sequential administration or simultaneous administration). The way in which the compositions are administered is not the primary point(s) of novelty of the present invention, but rather relate to standard administration practices for pharmaceutical compositions in general. Applicants respectfully submit that the species set forth in the Office Action are not independent inventions. Applicants respectfully request that the election of species requirement be reconsidered and withdrawn.

Applicants respectfully request that the requirements for election of species be reconsidered and withdrawn. Applicants believe that a full and complete reply has been made to the outstanding Office Action and, as such, the present application is in condition for allowance.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

Date: MAY 17, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

255599.1